Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
June 02, 2024 20:38 ET
|
Immutep Limited
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial...
Global HVDC Transmission Market: Comprehensive Overview, Trends and Analysis
June 02, 2024 20:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, June 02, 2024 (GLOBE NEWSWIRE) -- The HVDC Transmission Market is expected to reach USD 14.9 billion by 2028 from USD 11.4 billion in 2023, at a CAGR of 5.4% during the 2023–2028 period. ...
Mesoblast Corporate Presentation at Investor Conference
June 02, 2024 20:23 ET
|
Mesoblast Limited
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr....
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
June 02, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that results from FRUTIGA,...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2024 19:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
June 02, 2024 18:43 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License...
Duck Creek Technologies เสริมความแข็งแกร่งให้กับสถานะในตลาดเอเชียแปซิฟิกด้วยการแต่งตั้ง Christian Erickson ให้ดำรงตำแหน่งผู้จัดการทั่วไป
June 02, 2024 18:30 ET
|
Duck Creek Technologies
ซิดนีย์, June 03, 2024 (GLOBE NEWSWIRE) -- วันนี้ Duck Creek Technologies ผู้ให้บริการโซลูชันอัจฉริยะที่กำหนดอนาคตของทรัพย์สินและอุบัติเหตุ (P&C) และการประกันภัยทั่วไป ได้ประกาศแต่งตั้ง Bindu...
Duck Creek Technologies strengthens APAC presence with appointment of Christian Erickson as General Manager
June 02, 2024 18:30 ET
|
Duck Creek Technologies
SYDNEY, June 02, 2024 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, has announced the...
Biognosys lance Spectronaut 19 et présente les avancées dans ses plateformes de recherche lors de la conférence annuelle de l’ASMS 2024
June 02, 2024 18:20 ET
|
Biognosys AG
Spectronaut® 19 comporte des améliorations importantes dans les domaines de l’identification, de la découverte de candidats, de l’évolutivité pour l’analyse à grande échelle et de la prise en charge...
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
June 02, 2024 17:30 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received...
- June 02, 2024 19:00 ET Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- June 02, 2024 17:07 ET Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year